04:17 AM EST, 12/09/2024 (MT Newswires) -- Arcellx ( ACLX ) said Sunday preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.

Results from the trial at median follow-up of 9.5 months also showed a complete response/stringent complete response rate of 62% with no delayed neurotoxicities, the company said.

Meanwhile, the median progression-free survival and overall survival were not reached, Arcellx ( ACLX ) said, adding that three deaths "occurred due to treatment-emergent adverse events."

Multiple myeloma is a type of hematological cancer that can cause bone lesions, loss of bone density and bone fractures, the company said.